Integrated nanosensors to determine levels and functional activity of human telomerase

Neoplasia

Volumn 10, Issue 10, 2008, Pages 1066-1072

  Perez, J Manuel ^a   Grimm, Jan ^b   Josephson, Lee ^c   Weissleder, Ralph ^c  

^a UNIVERSITY OF CENTRAL FLORIDA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MAGNETISM; NANOSENSOR; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 54249139118     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08350     Document Type: Article

References (34)

1. Blackburn EH (2000). Telomeres and telomerase. Keio J Med 49, 59-65.
2. van Steensel B and de Lange T (1997). Control of telomere length by the human telomeric protein TRF1. Nature 385, 740-743.
3. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, and Shay JW (1994). Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011-2015.
4. Shay JW and Bacchetti S (1997). A survey of telomerase activity in human cancer. Eur J Cancer 33, 787-791.
5. Shay JW and Wright WE (2006). Telomerase therapeutics for cancer: challenges and new directions. Nat Rev Drug Discov 5, 577-584.
6. Cheng AJ, Tang R, Wang JY, Chang JT, and Wang TC (1999). Polymerase chain reaction-based enzyme immunoassay for quantitation of telomerase activity: application to colorectal cancers. Jpn J Cancer Res 90, 280-285.
7. Xia Y, Lin RX, Zheng SJ, Yang Y, Bo XC, Zhu DY, and Wang SQ (2005). Effective siRNA targets screening for human telomerase reverse transcriptase. World J Gastroenterol 11, 2497-2501.
8. Wu YY, Hruszkewycz AM, Delgado RM, Yang A, Vortmeyer AO, Moon YW, Weil RJ, Zhuang Z, and Remaley AT (2000). Limitations on the quantitative determination of telomerase activity by the electrophoretic and ELISA based TRAP assays. Clin Chim Acta 293, 199-212.
9. Rosi NL and Mirkin CA (2005). Nanostructures in biodiagnostics. Chem Rev 105, 1547-1562.
10. Josephson L, Tung CH, Moore A, and Weissleder R (1999). High-efficiency intracellular magnetic labeling with novel superparamagnetic-tat peptide conjugates. Bioconjug Chem 10, 186-191.
11. Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, Scadden DT, and Weissleder R (2000). Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 18, 410-414.
12. Josephson L, Perez JM, and Weissleder R (2001). Magnetic nanosensors for the detection of oligonucleotide sequences. Angew Chem Int Ed 40, 3204.
13. Perez JM, Josephson L, O'Loughlin T, Hogemann D, and Weissleder R (2002). Magnetic relaxation switches capable of sensing molecular interactions. Nat Biotechnol 20, 816-820.
14. Eller MS, Li GZ, Firoozabadi R, Puri N, and Gilchrest BA (2003). Induction of a p95/Nbs1-mediated S phase checkpoint by telomere 3′ overhang specific DNA. FASEB J 17, 152-162.
15. Eller MS, Ostrom K, and Gilchrest BA (1996). DNA damage enhances melanogenesis. Proc Natl Acad Sci USA 93, 1087-1092.
16. Puri N, Eller MS, Byers HR, Dykstra S, Kubera J, and Gilchrest BA (2004). Telomere-based DNA damage responses: a new approach to melanoma. FASEB J 18, 1373-1381.
17. Grimm J, Perez JM, Josephson L, and Weissleder R (2004). Novel nanosensors for rapid analysis of telomerase activity. Cancer Res 64, 639-643.
18. Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ, and Reddel RR (2007). Protein composition of catalytically active human telomerase from immortal cells. Science 315, 1850-1853.
19. Cakir C, Gulluoglu MG, and Yilmazbayhan D (2006). Cell proliferation rate and telomerase activity in the differential diagnosis between benign and malignant mesothelial proliferations. Pathology 38, 10-15.
20. Carvalho L, Lipay M, Belfort F, Santos I, Andrade J, Haddad A, Brunstein F, and Ferreira L (2006). Telomerase activity in prognostic histopathologic features of melanoma. J Plast Reconstr Aesthet Surg 59, 961-968.
21. Glaessl A, Bosserhoff AK, Buettner R, Hohenleutner U, Landthaler M, and Stolz W (1999). Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas. Arch Dermatol Res 291, 81-87.
22. Li S, Crothers J, Haqq CM, and Blackburn EH (2005). Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA. J Biol Chem 280, 23709-23717.
23. Lee H, Sun EY, Ham D, and Weissleder R (2008). Chip-NMR biosensor for detection and molecular analysis of cells. Nature advance online publication, 6 July 2008 (DOI: 10.1038\nml711).
24. Hogemann D, Ntziachristos V, Josephson L, and Weissleder R (2002). High throughput magnetic resonance imaging for evaluating targeted nanoparticle probes. Bioconjug Chem 13, 116-121.
25. Rudin M and Weissleder R (2003). Molecular imaging in drug discovery and development. Nat Rev Drug Discov 2, 123-131.
26. Hiyama E, Hiyama K, Yokoyama T, and Shay JW (2001). Immunohistochemical detection of telomerase (hTERT) protein in human cancer tissues and a subset of cells in normal tissues. Neoplasia 3, 17-26.
27. Bagheri S, Nosrati M, Li S, Fong S, Torabian S, Rangel J, Moore DH, Federman S, Laposa RR, Baehner FL, et al. (2006). Genes and pathways downstream of telomerase in melanoma metastasis. Proc Natl Acad Sci USA 103, 11306-11311.
28. Krams M, Claviez A, Heidorn K, Krupp G, Parwaresch R, Harms D, and Rudolph P (2001). Regulation of telomerase activity by alternate splicing of human telomerase reverse transcriptase mRNA in a subset of neuroblastomas. Am J Pathol 159, 1925-1932.
29. Kim YW, Hur SY, Kim TE, Lee JM, Namkoong SE, Ki IK, and Kim JW (2001). Protein kinase C modulates telomerase activity in human cervical cancer cells. Exp Mol Med 33, 156-163.
30. Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, Chauhan D, Richardson P, Munshi NC, and Anderson KC (2002). Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res 62, 3876-3882.
31. Ohyashiki JH, Hisatomi H, Nagao K, Honda S, Takaku T, Zhang Y, Sashida G, and Ohyashiki K (2005). Quantitative relationship between functionally active telomerase and major telomerase components (hTERT and hTR) in acute leukaemia cells. Br J Cancer 92, 1942-1947.
32. Ramirez RD, D'Atri S, Pagani E, Faraggiana T, Lacal PM, Taylor RS, and Shay JW (1999). Progressive increase in telomerase activity from benign melanocytic conditions to malignant melanoma. Neoplasia 1, 42-49.
33. Perlo J, Demas V, Casanova F, Meriles CA, Reimer J, Pines A, and Blumich B (2005). High-resolution NMR spectroscopy with a portable single-sided sensor. Science 308, 1279.
34. Lowery TJ, Palazzolo R, Wong SM, Prado PJ, and Taktak S (2008). Single-coil, multisample, proton relaxation method for magnetic relaxation switch assays. Anal Chem 80, 1118-1123.